08:00 , Dec 4, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic lymphocytic leukemia (CLL) Fas apoptotic inhibitory molecule 3 (FAIM3; TOSO) In vitro and mouse studies suggest...
08:00 , Feb 6, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Multiple sclerosis (MS) Fas apoptotic inhibitory molecule 3 (FAIM3; TOSO) Mouse studies suggest inhibiting the surface...
08:00 , Dec 8, 2011 |  BC Innovations  |  Targets & Mechanisms

Xa and IX mark the clot

Two research teams have separately reported engineered variants of clotting factors Xa and IX that could become next-generation hemophilia therapies.1,2Pfizer Inc. has exclusively licensed the factor Xa variant, while an undisclosed company has licensed the...
07:00 , Aug 28, 2008 |  BC Innovations  |  Cover Story

Armed & Dangerous

Researchers at the Burnham Institute for Medical Researchare taking a second shot at exploiting Salmonella's tumor-homing ability to develop cancer therapies. In work reported in the Journal of the National Cancer Institute, they armed an...
07:00 , Apr 27, 1998 |  BC Week In Review  |  Company News

Rigel Inc. other research news

Rigel researchers and colleagues published in Immunity the identification of toso, an integral membrane protein expressed in lymphoid cells that inhibits the apoptosis of T cells mediated by Fas and members of the TNF receptor...